Evidence map›Paper›PMID 41836103›Full record

ArticleSynthetic biology (Oxford, England)2026

A protein-fragment complementation assay to quantify synthetic protein scaffold efficiency.

Pascale Lemieux, Alexandre K Dubé, Christian R Landry

Abstract read
In one paragraph

Article in Synthetic biology (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Pascale LemieuxInstitut de Biologie Intégrative et des Systèmes (IBIS), Université Laval, Québec G1V 0A6, QC, Canada.ORCID https://orcid.org/0000-0002-4306-0527
Alexandre K DubéInstitut de Biologie Intégrative et des Systèmes (IBIS), Université Laval, Québec G1V 0A6, QC, Canada.ORCID https://orcid.org/0000-0001-8718-9894
Christian R LandryInstitut de Biologie Intégrative et des Systèmes (IBIS), Université Laval, Québec G1V 0A6, QC, Canada.ORCID https://orcid.org/0000-0003-3028-6866

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Scaffolds are powerful tools in synthetic biology used for various applications, from increasing yield to optimizing signalling specificity. Protein scaffolds can be built by fusing peptide binding domains (PBD) and attaching the peptide they bind to enzymes, inducing spatial proximity. Only a few PBD-peptide combinations have been tested in this context, and no combination produced a high yield in yeast, an important chassis in biotechnology. Therefore, there is a need for more exploration of PBD-peptide pairs to be used in this model. Scaffold characterization is challenging because it is often dependent on a model pathway with an output that is difficult to measure quantitatively. Here, we use the dihydrofolate reductase protein-fragment complementation assay (DHFR PCA) to study scaffolding efficiency in yeast, which allows to couple scaffolding efficiency with growth rate. First, we characterize the strength of PBD-peptide interactions (PPI) and the binding availability of the PBDs and peptides. Then, we test different scaffold architectures and expression levels to quantify the simultaneous binding of peptide pairs to the scaffold. We show that PPI strength of the weakest binding PBD-peptide pair is critical for scaffolding efficiency and that PPI strength is limited by low binding availability of some domains and peptides

Indexed as

DHFR PCAPDZ domainSH3 domainsynthetic protein scaffold

Identifiers

PMID41836103
PMCPMC12981675

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.